Table: Santen Pharm -Q1 group results (IFRS)

SANTEN PHARMACEUTICAL

01/08/2017 07:00

Aug 1 (Reuters)-  
              Santen Pharmaceutical Co Ltd  
              CONSOLIDATED FINANCIAL HIGHLIGHTS  
     (in billions of yen unless specified)  
                   3 months ended      3 months ended       Year to  
                  Jun 30, 2017        Jun 30, 2016     Mar 31, 2018  
                     LATEST             YEAR-AGO          COMPANY    
                     RESULTS             RESULT          FORECAST    
  Sales               55.95               50.01           218.00     
                   (+11.9 pct)         (+4.2 pct)       (+9.5 pct)   
  Operating           12.06               10.81            37.40     
                   (+11.5 pct)         (+0.1 pct)       (+15.2 pct)  
  Pretax              12.21               10.25            37.70     
                   (+19.1 pct)         (-8.7 pct)       (+18.5 pct)  
  Net                  8.92                7.32            26.90     
                   (+21.8 pct)         (-2.9 pct)       (+16.6 pct)  
  EPS Basic         21.96 yen           17.68 yen        66.23 yen   
  EPS Diluted       21.88 yen           17.61 yen                    
  Ann Div                               26.00 yen        26.00 yen   
  -Q2 Div                               13.00 yen        13.00 yen   
  -Q4 Div                               13.00 yen        13.00 yen   
  
  NOTE - Santen Pharmaceutical Co Ltd.  
  (Figures are reported based on international accounting rules (IFRS).)  
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half  
  dividend and Q4 to the second-half dividend announced before a new corporate law in  
  2006 allowed companies to pay and report dividends on a quarterly basis. 
  *Net - represents Net profit attributable to owners of the parent company.  
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T  
  ((Tokyo Headline News Desk +813 6441 1812))